Project Grant R44CA302357
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$1.1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Houston, TX 77021, USA
Similar Awards
The National Cancer Institute (NCI), through the Cancer Treatment Research program (CFDA 93.395), awarded a $1,999,703 project grant to March Biosciences Inc. to develop dual-targeting allogeneic chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma (TCL). The 2-year project aims to engineer partially-matched donor-derived CAR-T cells targeting both CD5 and CD7 antigens, which are expressed in...
This $1,108,391.72 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to define the most therapeutically relevant chimeric antigen receptor (CAR) T cell subsets for treating large B cell lymphoma (LBCL) and overcome immune suppression mechanisms that limit CAR T cell efficacy. The funded project will use a systems biology approach to analyze patient data and pinpoint optimal CAR T cell characteristics for...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
The National Cancer Institute (NCI) awarded a $1,477,396 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope in Duarte, CA. The grant, awarded on December 1, 2024, supports a novel approach to enhance the efficacy and durability of CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The project involves selecting cytomegalovirus (CMV)-specific T cells, modifying them with a...
This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $994,859 to Cytoagents Inc. to develop the compound CTO1681 for the prevention and treatment of cytokine release syndrome (CRS) associated with chimeric antigen receptor (CAR) T-cell therapy. Cytoagents is conducting a Phase 1b clinical trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of CTO1681 in reducing CRS and immune effector cell-associated neurotoxicity...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), awarded a $398,997 Project Grant to Immunogenik, Inc. in Gainesville, Florida. The grant supports the development and evaluation of a "3-in-1" Chimeric Antigen Receptor (CAR) T-cell therapy to enhance cancer treatment. The project aims to overcome limitations of current cancer therapies by targeting tumor-associated myeloid cells, which play a key role in cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to harness B cells after stem cell transplant to produce novel chimeric antigen receptor T-cells (CAR-Ts) for treating hematological malignancies. The $415,257 award to Duke University, a leading research institution, will fund research to clone antibody-producing B cells with tumor-binding potential after hematopoietic stem cell transplantation. The goal is to engineer less toxic and...
The National Cancer Institute (NCI) awarded a $798,512 Project Grant under CFDA 93.395 - Cancer Treatment Research to Luminary Therapeutics, Inc., a small disadvantaged business, to develop an allogeneic gamma/delta armored dual-targeting chimeric antigen receptor (CAR) T-cell therapy to treat epithelial ovarian carcinoma. The project aims to address key challenges with CAR T-cell therapies against solid tumors, including antigen escape and the immunosuppressive tumor microenvironment, through...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $691,118 in funding to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to establish a prospective cohort study of real-world multiple myeloma patients treated with chimeric antigen receptor (CAR) T-cell therapy. The study aims to evaluate the relationships between psychosocial factors (e.g., depression, anxiety, social support) and...